NASDAQ:ALNY Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free ALNY Stock Alerts $149.45 -4.94 (-3.20%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$149.32▼$154.5050-Day Range$146.51▼$189.7052-Week Range$143.52▼$218.88Volume666,592 shsAverage Volume702,111 shsMarket Capitalization$18.82 billionP/E RatioN/ADividend YieldN/APrice Target$216.12 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Alnylam Pharmaceuticals alerts: Email Address Alnylam Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside44.6% Upside$216.12 Price TargetShort InterestHealthy2.14% of Shares Sold ShortDividend StrengthN/ASustainability-1.52Upright™ Environmental ScoreNews Sentiment0.39Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.61) to ($2.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.84 out of 5 starsMedical Sector43rd out of 939 stocksPharmaceutical Preparations Industry20th out of 441 stocks 4.3 Analyst's Opinion Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 10 buy ratings, 8 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $216.12, Alnylam Pharmaceuticals has a forecasted upside of 44.6% from its current price of $149.45.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.14% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently decreased by 11.51%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlnylam Pharmaceuticals has received a 63.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Gene therapy medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alnylam Pharmaceuticals is -1.52. Previous Next 2.4 News and Social Media Coverage News SentimentAlnylam Pharmaceuticals has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Alnylam Pharmaceuticals this week, compared to 9 articles on an average week.Search InterestOnly 11 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.MarketBeat Follows5 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.40% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($4.61) to ($2.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is -41.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is -41.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Read More ALNY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALNY Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Receives "Outperform" Rating from BMO Capital MarketsMarch 26, 2024 | markets.businessinsider.comDecoding 12 Analyst Evaluations For Regeneron PharmaceuticalsMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alnylam Pharmaceuticals on Strong Commercial Business and Expanding CNS PipelineMarch 23, 2024 | americanbankingnews.comStockNews.com Upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) to "Buy"March 23, 2024 | americanbankingnews.comInvestors Purchase Large Volume of Alnylam Pharmaceuticals Call Options (NASDAQ:ALNY)March 20, 2024 | businesswire.comAlnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific SessionMarch 19, 2024 | finance.yahoo.comRapport Therapeutics Appoints Pioneering Industry Leader John Maraganore to Board of DirectorsMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 19, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Tenaya Therapeutics (TNYA)March 13, 2024 | businesswire.comAlnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive DiseaseMarch 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNYMarch 10, 2024 | seekingalpha.comIs Alnylam's HELIOS-B Delay A Red Flag?March 6, 2024 | finance.yahoo.comAlnylam, Roche blood pressure drug scores in second mid-stage trialMarch 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and IO Biotech (IOBT)March 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alnylam Pharma as Zilebesiran Shows Blockbuster PotentialMarch 5, 2024 | msn.comAlnylam, Roche mark second Phase 2 win for blood pressure therapyMarch 5, 2024 | finance.yahoo.comRoche, Alnylam say blood pressure drug succeeds in mid-stage trialMarch 5, 2024 | businesswire.comAlnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care AntihypertensivesMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNYMarch 1, 2024 | benzinga.comDecoding Regeneron Pharmaceuticals's Options Activity: What's the Big Picture?February 29, 2024 | markets.businessinsider.comOptimistic Buy Rating for BridgeBio Pharma Amid Strong Market Position and Promising Treatment PipelineFebruary 27, 2024 | finance.yahoo.comAlnylam to Webcast Presentations at Upcoming March Investor ConferencesFebruary 27, 2024 | businesswire.comAlnylam to Webcast Presentations at Upcoming March Investor ConferencesFebruary 23, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Alnylam Pharma (ALNY) and Bausch Health Companies (BHC)February 21, 2024 | finance.yahoo.comAlnylam Pharmaceuticals, Inc.: Alnylam Earnings: Robust Uptake of Amvuttra Drives Sales; Shares UndervaluedFebruary 21, 2024 | msn.comMarket Shifts: Upgrades and Downgrades Sweep Across Tech, Finance, and Healthcare StocksSee More Headlines Receive ALNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALNY CUSIP02043Q10 CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$216.12 High Stock Price Target$395.00 Low Stock Price Target$161.00 Potential Upside/Downside+44.6%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)($3.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-440,240,000.00 Net Margins-24.08% Pretax Margin-23.71% Return on EquityN/A Return on Assets-12.18% Debt Debt-to-Equity RatioN/A Current Ratio3.08 Quick Ratio2.99 Sales & Book Value Annual Sales$1.83 billion Price / Sales10.30 Cash FlowN/A Price / Cash FlowN/A Book Value($1.76) per share Price / Book-84.91Miscellaneous Outstanding Shares125,950,000Free Float124,183,000Market Cap$18.82 billion OptionableOptionable Beta0.39 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Yvonne L. Greenstreet M.B.A. (Age 61)MBChB, CEO & Director Comp: $2.09MMr. Jeffrey V. Poulton M.B.A. (Age 56)CFO & Executive VP Comp: $972.35kDr. Akshay K. Vaishnaw M.D. (Age 61)Ph.D., Chief Innovation Officer & Member of the Scientific Advisory Board Comp: $1.24MDr. Pushkal P. Garg M.D. (Age 56)Chief Medical Officer and Executive VP of Development & Medical Affairs Comp: $1MMr. Timothy J. MainesChief Technical Operations & Quality OfficerDr. Kevin Joseph Fitzgerald Ph.D. (Age 55)Senior VP, Head of Research & Chief Scientific Officer Ms. Christine Regan Lindenboom (Age 43)Senior VP of Investor Relations & Corporate Communications Mr. Piyush Sharma J.D.Chief Ethics & Compliance OfficerMr. Evan LippmanChief Corporate Development & Strategy OfficerMs. Kelley BoucherChief Human Resource OfficerMore ExecutivesKey CompetitorsRoyalty PharmaNASDAQ:RPRXBioMarin PharmaceuticalNASDAQ:BMRNMyoKardiaNASDAQ:MYOKUnited TherapeuticsNASDAQ:UTHRHorizon Therapeutics PublicNASDAQ:HZNPView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Sold 2,547 shares on 3/22/2024Ownership: 0.010%Vanguard Group Inc.Bought 287,064 shares on 3/11/2024Ownership: 9.483%Goldman Sachs Group Inc.Sold 20,677 shares on 3/1/2024Ownership: 0.231%Teachers Retirement System of The State of KentuckySold 21,042 shares on 2/26/2024Ownership: 0.024%V Square Quantitative Management LLCBought 274 shares on 2/21/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.: Alnylam Pharmaceuticals focuses on developing novel therapeutics based on ribonucleic acid interference, a cutting-edge technology in the pharmaceutical industry that has shown promising results in treating various diseases. The company has a diverse pipeline of investigational RNAi therapeutics targeting genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases, indicating potential for multiple revenue streams. Alnylam Pharmaceuticals has a strong portfolio of marketed products including ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO, addressing rare diseases with high unmet medical needs, which can lead to stable revenue generation. Strategic collaborations with reputable companies like Regeneron Pharmaceuticals and Roche demonstrate Alnylam's ability to leverage partnerships for research, development, and commercialization, enhancing growth prospects. Recent positive market ratings and institutional ownership trends for Alnylam Pharmaceuticals, as well as the stock's performance, indicate investor confidence and potential for stock price appreciation. Cons Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons: Alnylam Pharmaceuticals operates in the highly competitive biopharmaceutical industry, facing challenges such as regulatory hurdles, clinical trial failures, and potential market saturation, which can impact financial performance. The company's focus on rare diseases may limit its addressable market and scalability compared to companies targeting more prevalent conditions, potentially affecting long-term growth prospects. Risks associated with clinical trial outcomes, drug approvals, and intellectual property protection are inherent in the biopharmaceutical sector, leading to uncertainties in revenue streams and profitability. Dependency on a few key products for revenue generation exposes Alnylam Pharmaceuticals to risks of market fluctuations, patent expirations, and competition from emerging therapies, affecting financial stability. Investing in pharmaceutical companies like Alnylam Pharmaceuticals carries inherent market risks, including macroeconomic factors, regulatory changes, and healthcare policy shifts that can influence stock performance and investor returns. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, March 25, 2024. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com. ALNY Stock Analysis - Frequently Asked Questions Should I buy or sell Alnylam Pharmaceuticals stock right now? 18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALNY shares. View ALNY analyst ratings or view top-rated stocks. What is Alnylam Pharmaceuticals' stock price target for 2024? 18 analysts have issued 12-month price objectives for Alnylam Pharmaceuticals' stock. Their ALNY share price targets range from $161.00 to $395.00. On average, they anticipate the company's share price to reach $216.12 in the next twelve months. This suggests a possible upside of 44.6% from the stock's current price. View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts. How have ALNY shares performed in 2024? Alnylam Pharmaceuticals' stock was trading at $191.41 at the start of the year. Since then, ALNY stock has decreased by 21.9% and is now trading at $149.45. View the best growth stocks for 2024 here. Are investors shorting Alnylam Pharmaceuticals? Alnylam Pharmaceuticals saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 2,690,000 shares, a decline of 11.5% from the February 29th total of 3,040,000 shares. Based on an average daily volume of 834,900 shares, the short-interest ratio is currently 3.2 days. View Alnylam Pharmaceuticals' Short Interest. When is Alnylam Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ALNY earnings forecast. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.20) by $0.10. The biopharmaceutical company earned $439.72 million during the quarter, compared to analysts' expectations of $439.38 million. The firm's revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.68) earnings per share. What ETFs hold Alnylam Pharmaceuticals' stock? ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Morningstar US Small Growth (MSGR), Amplify Treatments, Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), VanEck Biotech ETF (BBH), Principal Healthcare Innovators ETF (BTEC) and VictoryShares Nasdaq Next 50 ETF (QQQN). What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings? Alnylam Pharmaceuticals issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.7 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion. What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO? 65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD). Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital World Investors (12.89%), Vanguard Group Inc. (9.52%), Vanguard Group Inc. (9.48%), Baillie Gifford & Co. (5.55%), Dodge & Cox (2.92%) and Capital International Investors (2.86%). Insiders that own company stock include Akshay Vaishnaw, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Michael W Bonney, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALNY) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.